These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 26929418)

  • 1. Short-course treatment for multidrug-resistant tuberculosis: the STREAM trials.
    Moodley R; Godec TR;
    Eur Respir Rev; 2016 Mar; 25(139):29-35. PubMed ID: 26929418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial.
    Bouton TC; Phillips PPJ; Mitnick CD; Peloquin CA; Eisenach K; Patientia RF; Lecca L; Gotuzzo E; Gandhi NR; Butler D; Diacon AH; Martel B; Santillan J; Hunt KR; Vargas D; von Groote-Bidlingmaier F; Seas C; Dianis N; Moreno-Martinez A; Horsburgh CR
    Trials; 2017 Nov; 18(1):563. PubMed ID: 29178937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial.
    Nunn AJ; Rusen ID; Van Deun A; Torrea G; Phillips PP; Chiang CY; Squire SB; Madan J; Meredith SK
    Trials; 2014 Sep; 15():353. PubMed ID: 25199531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
    Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J
    Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chinese herbal medicine as adjuvant treatment to chemotherapy for multidrug-resistant tuberculosis (MDR-TB): A systematic review of randomised clinical trials.
    Wang M; Guan X; Chi Y; Robinson N; Liu JP
    Tuberculosis (Edinb); 2015 Jul; 95(4):364-72. PubMed ID: 25861717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profile of delamanid for the treatment of multidrug-resistant tuberculosis.
    Szumowski JD; Lynch JB
    Drug Des Devel Ther; 2015; 9():677-82. PubMed ID: 25678771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bedaquiline as part of combination therapy in adults with pulmonary multi-drug resistant tuberculosis.
    Nguyen TV; Cao TB; Akkerman OW; Tiberi S; Vu DH; Alffenaar JW
    Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1025-37. PubMed ID: 27322153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging strategies for the treatment of pulmonary tuberculosis: promise and limitations?
    Yew WW; Koh WJ
    Korean J Intern Med; 2016 Jan; 31(1):15-29. PubMed ID: 26767853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of moxifloxacin in tuberculosis therapy.
    Gillespie SH
    Eur Respir Rev; 2016 Mar; 25(139):19-28. PubMed ID: 26929417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
    Centers for Disease Control and Prevention
    MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis.
    Becerra MC; Freeman J; Bayona J; Shin SS; Kim JY; Furin JJ; Werner B; Sloutsky A; Timperi R; Wilson ME; Pagano M; Farmer PE
    Int J Tuberc Lung Dis; 2000 Feb; 4(2):108-14. PubMed ID: 10694087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implementation of multidrug-resistant tuberculosis (MDR-TB) treatment in Gabon: lessons learnt from the field.
    Ateba-Ngoa U; Edoa JR; Adegbite BR; Rossatanga EG; Madiou D; Mfoumbi A; Mevyann C; Achimi Agbo P; Mahoumbou J; Gould S; Lell B; Adegnika AA; Köhler C; Kremsner PG; Massinga-Loembe M; Alabi A; Grobusch MP
    Infection; 2019 Oct; 47(5):811-816. PubMed ID: 31073710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial.
    Guglielmetti L; Ardizzoni E; Atger M; Baudin E; Berikova E; Bonnet M; Chang E; Cloez S; Coit JM; Cox V; de Jong BC; Delifer C; Do JM; Tozzi DDS; Ducher V; Ferlazzo G; Gouillou M; Khan A; Khan U; Lachenal N; LaHood AN; Lecca L; Mazmanian M; McIlleron H; Moschioni M; O'Brien K; Okunbor O; Oyewusi L; Panda S; Patil SB; Phillips PPJ; Pichon L; Rupasinghe P; Rich ML; Saluhuddin N; Seung KJ; Tamirat M; Trippa L; Cellamare M; Velásquez GE; Wasserman S; Zimetbaum PJ; Varaine F; Mitnick CD
    Trials; 2021 Sep; 22(1):651. PubMed ID: 34563240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh.
    Van Deun A; Salim MA; Das AP; Bastian I; Portaels F
    Int J Tuberc Lung Dis; 2004 May; 8(5):560-7. PubMed ID: 15137531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Park SK; Kim JH; Kang H; Cho JS; Smego RA
    Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.
    Nahid P; Mase SR; Migliori GB; Sotgiu G; Bothamley GH; Brozek JL; Cattamanchi A; Cegielski JP; Chen L; Daley CL; Dalton TL; Duarte R; Fregonese F; Horsburgh CR; Ahmad Khan F; Kheir F; Lan Z; Lardizabal A; Lauzardo M; Mangan JM; Marks SM; McKenna L; Menzies D; Mitnick CD; Nilsen DM; Parvez F; Peloquin CA; Raftery A; Schaaf HS; Shah NS; Starke JR; Wilson JW; Wortham JM; Chorba T; Seaworth B
    Am J Respir Crit Care Med; 2019 Nov; 200(10):e93-e142. PubMed ID: 31729908
    [No Abstract]   [Full Text] [Related]  

  • 18. Modelling the effect of short-course multidrug-resistant tuberculosis treatment in Karakalpakstan, Uzbekistan.
    Trauer JM; Achar J; Parpieva N; Khamraev A; Denholm JT; Falzon D; Jaramillo E; Mesic A; du Cros P; McBryde ES
    BMC Med; 2016 Nov; 14(1):187. PubMed ID: 27855693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictor of multidrug resistant tuberculosis in southwestern part of Ethiopia: a case control study.
    Gobena D; Ameya G; Haile K; Abreha G; Worku Y; Debela T
    Ann Clin Microbiol Antimicrob; 2018 Jul; 17(1):30. PubMed ID: 29970076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives.
    Pontali E; Raviglione MC; Migliori GB;
    Eur Respir Rev; 2019 Jun; 28(152):. PubMed ID: 31142549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.